No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART

AIDS Research and Human Retroviruses

Volumn 23, Issue 8, 2007, Pages 983-987

  Takahashi, Masaaki ^a   Ibe, Shiro ^a   Kudaka, Yuichi ^a   Okumura, Naoya ^a   Hirano, Atsushi ^a   Suzuki, Tatsuo ^a   Mamiya, Naoto ^a   Hamaguchi, Motohiro ^a   Kaneda, Tsuguhiro ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ;

ABNORMAL DREAMING; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; FEMALE; HALLUCINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAPANESE; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NERVOUSNESS; PRIORITY JOURNAL; RASH; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; JAPAN; MALE; MIDDLE AGED; VIRAL LOAD;

EID: 34848907106     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0193     Document Type: Article

References (22)

1. Adkins JC and Noble S: Efavirenz. Drugs 1998;56:1055-1064.
2. Bristol-Myers Squibb Company: Product information, Sustiva (efavirenz). Princeton, NJ, 2003.
3. Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, Kornhauser DM, Fiske W, Vincent C, Lischner HW, Dankner WM, and Flynn PM: Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999;341:1874-1881.
4. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, and Ruiz NM: Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-1873.
5. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro J, Telenti A, and Richman D: Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005;13:51-57.
6. Langmann P, Weissbrich B, Desch S, Vath T, Schirmer D, Zilly M, and Klinker H: Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-I infected patients. Eur J Med Res 2002;7:309-314.
7. Nunez M, Gonzalez de Requena D, Gallego L, Jimenez-Nacher I, Gonzalez-Lahoz J, and Soriano V: Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001;28:399-400.
8. Gallego L, Barreiro P, del Rio R, Gonzalez de Requena D, Rodriguez-Albarino A, Gonzalez-Lahoz J, and Soriano V: Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clin Infect Dis 2004;38:430-432.
9. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, and Buclin T: Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75.
10. The Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS): Published at http://AIDSinfo.nih.gov, 7 April 2005.
11. Takahashi M, Yoshida M, Oki T, Okumura N, Suzuki T, and Kaneda T: Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. Biol Pharm Bull 2005;28:1286-1290.
12. Ibe S, Hotta N, Takeo U, Tawada Y, Mamiya N, Yamanaka K, Utsumi M, and Kaneda T: Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing. Microbiol Immunol 2003;47:499-505.
13. Ibe S, Shibata N, Utsumi M, and Kaneda T: Selection of human immunodeficiency virus type 1 variants with an insertion mutation in the p6(gag) and p6(pol) genes under highly active antiretroviral therapy. Microbiol Immunol 2003;47:71-79.
14. Starcevic V, Bogojevic G, and Marinkovic J: The SCL-90-R as a screening instrument for severe personality disturbance among outpatients with mood and anxiety disorders. J Personal Disord 2000;14:199-207.
15. Gutierrez F, Navarro A, Padilla S, Anton R, Masia M, Borras J, and Martin-Hidalgo A: Prediction of neuropsychiatrie adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005;41:1648-1653.
16. Fumaz CR, Munoz-Moreno JA, Molto J, Negredo E, Ferrer MJ, Sirera G, Perez-Alvarez N, Gomez G, Burger D, and Clotet B: Long-term neuropsychiatrie disorders on efavirenz-based approaches: Quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 2005;38:560-565.
17. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM: Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 15: 399-415.
18. Stahle L, Moberg L, Svensson JO, and Sonnerborg A: Efavirenz plasma concentrations in HIV-infected patients: Inter- and intraindividual variability and clinical effects. Ther Drug Monit 2004;26:267-270.
19. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, and Acosta EP: Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS 2004;18:2391-2400.
20. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, and Oka S: Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004;319:1322-1326.
21. Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, and Telenti A, Swiss HIV Cohort Study: Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005;15:1-5.
22. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, and Gulick RM, the A5097s study team: Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann In-tern Med 2005;143:714-721.